Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chava Perry

Showing results (71-80 of 72) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 72 results.
Annals of Hematology|January 27, 2022
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysisIrit Avivi, Chava Perry, Yafit Segman, et al.
American Journal of Hematology|February 26, 2020
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study groupYair Herishanu, Adir Shaulov, Riva Fineman, et al.
Pageof 8

Showing results (71-80 of 72) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 72 results.
Annals of Hematology|January 27, 2022
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysisIrit Avivi, Chava Perry, Yafit Segman, et al.
American Journal of Hematology|February 26, 2020
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study groupYair Herishanu, Adir Shaulov, Riva Fineman, et al.
Pageof 8